AstraZeneca Pharma India Limited has announced its unreviewed financial results for the quarter and half-year ended September 30, 2026. The company also disclosed the appointment of Mr. Krishnamurthy Narayanan Iyer as an Additional Director, and other key managerial personnel changes, including the appointment of Mr. Atul Tandon as Chief Financial Officer, effective November 9, 2026. The Board meeting also covered the appointment of Mr. Kumaran Krishnan as Medical Director, effective December 1, 2026.
AstraZeneca Pharma India Announces Q2 FY27 Unreviewed Financials and Key Appointments
AstraZeneca Pharma India Limited has publicly shared its unreviewed financial results for the quarter and the half-year ended September 30, 2026. These results were considered and approved by the company’s Board of Directors during a meeting held on Thursday, November 5, 2026. The financial statements, along with a Limited Review Report from the Statutory Auditors, have been duly enclosed with this announcement.
Key Leadership Changes Approved
In addition to the financial updates, the Board of Directors also approved several significant appointments and changes in senior management roles. Effective November 5, 2026, Mr. Krishnamurthy Narayanan Iyer has been appointed as an Additional Director (Non-Executive, Independent) for a term of five years, subject to shareholder approval. Furthermore, Mr. Atul Tandon has been appointed as the Chief Financial Officer, a Key Managerial Personnel, effective November 9, 2026. Following this, Mr. Nitin Bindal‘s designation has been changed to Director – Biopharmaceuticals Business Unit, also effective November 9, 2026. The company has also appointed Mr. Kumaran Krishnan as Medical Director – Biopharmaceuticals Business Unit, commencing December 1, 2026.
Publication of Financial Results
AstraZeneca Pharma India Limited is currently arranging to publish these unreviewed financial results in newspapers as per the stipulated SEBI Listing Regulations. The details for the aforementioned appointments and senior management role changes, as required under SEBI regulations, are enclosed as Annexure – A. The information is also available on the company’s website at www.astrazeneca.com/india.
Board Meeting Concluded
The Board of Directors’ meeting commenced at 1:30 p.m. and concluded at 3:50 p.m. on November 5, 2026.
Source: BSE
